Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Jonathan G. Pol; Sarah Lévesque; Samuel T. Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R. Clements; Jean Eudes Fahrner; Laetitia Fend; John C. Bell; Karen L. Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2018.1503032

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Medicine

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

70 Citas (Scopus)

Resumen

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

Idioma original	English
Número de artículo	e1503032
Publicación	OncoImmunology
Volumen	7
N.º	12
DOI	https://doi.org/10.1080/2162402X.2018.1503032
Estado	Published - dic. 2 2018

Nota bibliográfica

Funding Information:
SL, STW, FLB, SG, DRC, KLM, GK and LG have no conflicts of interest to declare. JGP and JCB share ownership of a patent for cancer vaccine composition involving oncolytic Maraba MG1 (publication number: EP2958994A1). JCB is a co-founder, equity holder and on the Board of Directors of Turnstone Biologics. JEF and LF are, respectively, funded by and employee of Transgene. LZ is on the Board of Directors of Transgene.

Publisher Copyright:
© 2018, © 2018 Taylor & Francis Group, LLC.

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology
Oncology

PubMed: MeSH publication types

Journal Article
Review
Research Support, Non-U.S. Gov't

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1080/2162402X.2018.1503032

Otros archivos y enlaces

Citar esto

G. Pol, J., Lévesque, S., Workenhe, S. T., Gujar, S., Le Boeuf, F., R. Clements, D., Fahrner, J. E., Fend, L., C. Bell, J., L. Mossman, K., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018). Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology, 7(12), Artículo e1503032. https://doi.org/10.1080/2162402X.2018.1503032

@article{7f9acee98c254b8c8499968a869b8f4b,

title = "Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors",

abstract = "Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.",

author = "{G. Pol}, Jonathan and Sarah L{\'e}vesque and Workenhe, {Samuel T.} and Shashi Gujar and {Le Boeuf}, Fabrice and {R. Clements}, Derek and Fahrner, {Jean Eudes} and Laetitia Fend and {C. Bell}, John and {L. Mossman}, Karen and Jitka Fucikova and Radek Spisek and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi",

note = "Funding Information: SL, STW, FLB, SG, DRC, KLM, GK and LG have no conflicts of interest to declare. JGP and JCB share ownership of a patent for cancer vaccine composition involving oncolytic Maraba MG1 (publication number: EP2958994A1). JCB is a co-founder, equity holder and on the Board of Directors of Turnstone Biologics. JEF and LF are, respectively, funded by and employee of Transgene. LZ is on the Board of Directors of Transgene. Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Taylor & Francis Group, LLC.",

year = "2018",

month = dec,

day = "2",

doi = "10.1080/2162402X.2018.1503032",

language = "English",

volume = "7",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "12",

}

TY - JOUR

T1 - Trial Watch

T2 - Oncolytic viro-immunotherapy of hematologic and solid tumors

AU - G. Pol, Jonathan

AU - Lévesque, Sarah

AU - Workenhe, Samuel T.

AU - Gujar, Shashi

AU - Le Boeuf, Fabrice

AU - R. Clements, Derek

AU - Fahrner, Jean Eudes

AU - Fend, Laetitia

AU - C. Bell, John

AU - L. Mossman, Karen

AU - Fucikova, Jitka

AU - Spisek, Radek

AU - Zitvogel, Laurence

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

N1 - Funding Information: SL, STW, FLB, SG, DRC, KLM, GK and LG have no conflicts of interest to declare. JGP and JCB share ownership of a patent for cancer vaccine composition involving oncolytic Maraba MG1 (publication number: EP2958994A1). JCB is a co-founder, equity holder and on the Board of Directors of Turnstone Biologics. JEF and LF are, respectively, funded by and employee of Transgene. LZ is on the Board of Directors of Transgene. Publisher Copyright: © 2018, © 2018 Taylor & Francis Group, LLC.

PY - 2018/12/2

Y1 - 2018/12/2

N2 - Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

AB - Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85058014194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058014194&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2018.1503032

DO - 10.1080/2162402X.2018.1503032

M3 - Review article

C2 - 30524901

AN - SCOPUS:85058014194

SN - 2162-4011

VL - 7

JO - OncoImmunology

JF - OncoImmunology

IS - 12

M1 - e1503032

ER -

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto